Carbonate ( DrugBank: Carbonate )


12 diseases
告示番号疾患名(ページ内リンク)臨床試験数
2筋萎縮性側索硬化症10
13多発性硬化症/視神経脊髄炎2
17多系統萎縮症2
18脊髄小脳変性症(多系統萎縮症を除く。)2
19ライソゾーム病2
46悪性関節リウマチ1
53シェーグレン症候群1
75クッシング病1
96クローン病1
127前頭側頭葉変性症1
235副甲状腺機能低下症5
299嚢胞性線維症1

2. 筋萎縮性側索硬化症


臨床試験数 : 624 薬物数 : 623 - (DrugBank : 160) / 標的遺伝子数 : 172 - 標的パスウェイ数 : 225
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2020-000579-19-NL
(EUCTR)
25/06/202129/03/2021An international multi-center clinical trial to investigate the efficacy of multiple drug compounds in patients with Amyotrophic Lateral Sclrerosis (ALS).A Multi-arm, Adaptive, Group-sequential trial NETwork to evaluate drug efficacy in patients with Amyotrophic Lateral Sclerosis (ALS) - MAGNET Amyotrophic Lateral Sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: Lithium Carbonate
INN or Proposed INN: Lithium carbonate
Other descriptive name: LITHIUM CARBONATE
Stichting TRICALS FoundationNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
171Phase 3Belgium;Ireland;Australia;Netherlands;United Kingdom;Sweden
2EUCTR2008-006722-34-IT
(EUCTR)
23/06/200911/12/2008Multicentric randomized placebo controlled trial of Lithium carbonate combined with Riluzole in patients with ALS - RCT ALS LithiumMulticentric randomized placebo controlled trial of Lithium carbonate combined with Riluzole in patients with ALS - RCT ALS Lithium Amyotrophic Lateral Sclerosis
MedDRA version: 9.1;Level: LLT;Classification code 10002026;Term: Amyotrophic lateral sclerosis
Trade Name: CARBOLITHIUM
INN or Proposed INN: Lithium
ISTITUTO SUPERIORE DI SANITA`NULLNot RecruitingFemale: yes
Male: yes
Italy
3EUCTR2008-006224-61-ES
(EUCTR)
12/06/200904/05/2009Ensayo clínico multicéntrico, aleatorizado, controlado para evaluar la eficacia del tratamiento con carbonato de litio en pacientes con Esclerosis Lateral AmiotróficaEnsayo clínico multicéntrico, aleatorizado, controlado para evaluar la eficacia del tratamiento con carbonato de litio en pacientes con Esclerosis Lateral Amiotrófica Esclerosis Lateral Amiotrófica
MedDRA version: 9;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis
Trade Name: PLENUR
INN or Proposed INN: LITIO CARBONATO
Other descriptive name: LITHIUM CARBONATE
Institut de Recerca de l'Hospital de la Santa Creu i Sant PauNULLNot RecruitingFemale: yes
Male: yes
Spain
4NCT00925847
(ClinicalTrials.gov)
June 200919/6/2009Effect of Lithium Carbonate in Patients With Amyotrophic Lateral SclerosisOpen Multicenter Study of Lithium in Patients With Amyotrophic Lateral Sclerosis LISLAAmyotrophic Lateral SclerosisDrug: lithiumAssistance Publique - Hôpitaux de ParisNULLCompleted18 YearsN/ABoth23Phase 2France
5EUCTR2008-005106-38-ES
(EUCTR)
14/05/200926/02/2009ENSAYO CLÍNICO RANDOMIZADO DOBLE CIEGO DE CARBONATO DE LITIO COMO TERAPIA DE ASOCIACIÓN EN ESCLEROSIS LATERAL AMIOTRÓFICA (FASE II) - LIELAENSAYO CLÍNICO RANDOMIZADO DOBLE CIEGO DE CARBONATO DE LITIO COMO TERAPIA DE ASOCIACIÓN EN ESCLEROSIS LATERAL AMIOTRÓFICA (FASE II) - LIELA Esclerosis Lateral Amiotrofica
MedDRA version: 9.1;Level: LLT;Classification code 10002026;Term: Amyotrophic lateral sclerosis
Trade Name: PLENUR
INN or Proposed INN: LITIO CARBONATO
Other descriptive name: LITHIUM CARBONATE
Lucia Galan Hospital Clinico San CarlosNULLNot RecruitingFemale: yes
Male: yes
280Spain
6EUCTR2008-006891-31-GB
(EUCTR)
17/02/200928/07/2010A randomised placebo-controlled trial of Lithium carbonate in Amyotrophic Lateral Sclerosis (LiCALS) - LiCALSA randomised placebo-controlled trial of Lithium carbonate in Amyotrophic Lateral Sclerosis (LiCALS) - LiCALS Amyotrophic Lateral Sclerosis (ALS)
MedDRA version: 9.1;Level: LLT;Classification code 10002026;Term: Amyotrophic lateral sclerosis
Trade Name: Lithium Apogepha
Product Name: Lithium Carbonate
Other descriptive name: LITHIUM CARBONATE
Trade Name: Lithium Carbonate
Product Name: Lithium Carbonate
Other descriptive name: LITHIUM CARBONATE
Trade Name: Lithium Citrate
Product Name: Lithium Citrate
Other descriptive name: LITHIUM CITRATE
King's College LondonNULLNot RecruitingFemale: yes
Male: yes
220Phase 4United Kingdom
7NCT00818389
(ClinicalTrials.gov)
January 20096/1/2009Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS)A Multicenter, Double-Blind, Placebo-Controlled, Study to Investigate the Safety and Efficacy of Lithium in Combination With Riluzole in Volunteers With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisDrug: Lithium Carbonate;Drug: Riluzole;Drug: placeboMassachusetts General HospitalALS Association;ALS Society of Canada;National Institute of Neurological Disorders and Stroke (NINDS);University of Toronto;State University of New York - Upstate Medical University;Columbia University;University of KentuckyTerminated18 YearsN/AAll84Phase 2/Phase 3United States;Canada
8EUCTR2008-003707-32-FR
(EUCTR)
09/10/200822/08/2008Etude de l'effet du carbonate de lithium sur une population de patients atteints de SLA en ouvert en comparaison avec une population de référence. LISLA - LISLAEtude de l'effet du carbonate de lithium sur une population de patients atteints de SLA en ouvert en comparaison avec une population de référence. LISLA - LISLA Patient atteint de sclérose latérale amyotrophique.
MedDRA version: 8.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis
Trade Name: Téralithe LP
Product Name: Téralithe LP
INN or Proposed INN: Carbonate de lithium
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
France
9EUCTR2008-002110-22-NL
(EUCTR)
16/09/200805/08/2008A randomised sequential trial of Lithium in amyotrophic lateral sclerosis - Lithium in ALSA randomised sequential trial of Lithium in amyotrophic lateral sclerosis - Lithium in ALS Amyotrophic lateral sclerosis (ALS) is a disease characterised by progressive degeneration of motor neurons in brain and spinal cord leading to muscle weakness. ALS can occur at anytime in adulthood. Muscle weakness gradually progresses. Approximately 50% of patients die within 3 years after onset of symptoms, usually as the result of respiratory failure. To date, only one drug, i.e. riluzole, has proven to extend survival in patients with ALS, but only by approximately 3 to 6 months.
MedDRA version: 9.1;Level: LLT;Classification code 10052889;Term: ALS
Trade Name: Lithiumcarbonaat 400 PCH tabletten
Product Name: Lithiumcarbonaat
Other descriptive name: LITHIUM CARBONATE
Prof. dr L.H. van den Berg, UMC-UtrechtNULLNot RecruitingFemale: yes
Male: yes
Netherlands
10NCT00790582
(ClinicalTrials.gov)
May 200812/11/2008A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisDrug: lithium carbonateForbes Norris MDA/ALS Research CenterMuscular Dystrophy AssociationCompleted21 Years80 YearsAll109Phase 2United States

13. 多発性硬化症/視神経脊髄炎


臨床試験数 : 3,342 薬物数 : 2,380 - (DrugBank : 407) / 標的遺伝子数 : 266 - 標的パスウェイ数 : 240
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01259388
(ClinicalTrials.gov)
May 201110/12/2010A Pilot Study of Lithium in Progressive Multiple SclerosisA Pilot Trial of Lithium in Progressive Multiple SclerosisMultiple SclerosisDrug: Lithium CarbonateVA Office of Research and DevelopmentNULLCompleted30 Years65 YearsAll23Phase 1/Phase 2United States
2NCT00785473
(ClinicalTrials.gov)
January 20084/11/2008Can Vitamin D Supplementation Prevent Bone Loss in Persons With Multiple SclerosisCan Vitamin D Supplementation Prevent Bone Loss in Persons With MS? A Randomised, Placebo-controlled, Single-centre StudyMultiple Sclerosis, OsteoporosisDietary Supplement: cholecalciferol;Dietary Supplement: calcium carbonateUniversity Hospital of North NorwayNULLCompleted18 Years50 YearsBoth80Phase 4Norway

17. 多系統萎縮症


臨床試験数 : 118 薬物数 : 164 - (DrugBank : 49) / 標的遺伝子数 : 61 - 標的パスウェイ数 : 112
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2009-016377-15-IT
(EUCTR)
26/10/200926/10/2009DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL TO TEST THE EFFICACY, SAFETY AND TOLERABILITY OF LITHIUM IN MULTIPLE SYSTEM ATROPHY - Lithium in MSADOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL TO TEST THE EFFICACY, SAFETY AND TOLERABILITY OF LITHIUM IN MULTIPLE SYSTEM ATROPHY - Lithium in MSA Muliple system atrophy
MedDRA version: 9.1;Level: HLT;Classification code 10008028
Trade Name: LITIO CARBONATO
INN or Proposed INN: LITHIUM CARBONATE
UNIVERSITA` DEGLI STUDI DI NAPOLI FEDERICO IINULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy
2NCT00997672
(ClinicalTrials.gov)
October 200916/10/2009Lithium in Multiple System AtrophyA Double-blind, Randomized, Placebo-controlled Clinical Trial to Assess Efficacy, Safety and Tolerability of Lithium in Multiple System Atrophy.Multiple System AtrophyDrug: Lithium Carbonate;Drug: PlaceboFederico II UniversityNULLTerminated18 Years80 YearsAll10Phase 2Italy

18. 脊髄小脳変性症(多系統萎縮症を除く。)


臨床試験数 : 71 薬物数 : 101 - (DrugBank : 30) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 65
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01096082
(ClinicalTrials.gov)
May 201129/3/2010Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3Randomized Clinical Trial to Assess the Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3Spinocerebellar Ataxia Type 3;Machado Joseph DiseaseDrug: Lithium Carbonate;Drug: PlaceboHospital de Clinicas de Porto AlegreNULLCompleted16 Years80 YearsBoth62Phase 2/Phase 3Brazil
2NCT00683943
(ClinicalTrials.gov)
May 18, 200822/5/2008Lithium Treatment for Patients With Spinocerebellar Ataxia Type IPilot Study of Tolerability of Lithium Therapy in Patients With Spinocerebellar Ataxia Type I (SCA1)Spinocerebellar Ataxia Type IDrug: Lithium CarbonateNational Institute of Neurological Disorders and Stroke (NINDS)NULLCompleted18 Years65 YearsAll13Phase 1United States

19. ライソゾーム病


臨床試験数 : 854 薬物数 : 727 - (DrugBank : 105) / 標的遺伝子数 : 69 - 標的パスウェイ数 : 190
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03201627
(ClinicalTrials.gov)
July 5, 201726/6/2017Study of Lithium Carbonate to Treat Niemann-Pick Type C1 Diseasea Single-center, Prospective, Open, and Non-randomized Case-control Study of Lithium Carbonate Effect on Niemann Disease C1 TypeNiemann-Pick Disease, Type C1Drug: Lithium CarbonateXinhua Hospital, Shanghai Jiao Tong University School of MedicineNULLActive, not recruiting7 Years40 YearsAll18Early Phase 1China
2NCT00004488
(ClinicalTrials.gov)
October 199818/10/1999Phase II Randomized Study of Alendronate Sodium for Osteopenia in Patients With Gaucher's DiseaseGaucher's Disease;OsteopeniaDrug: alendronate sodium;Drug: calcium carbonate;Drug: cholecalciferolChildren's Hospital Medical Center, CincinnatiNULLCompleted18 Years50 YearsBoth82Phase 2United States;Israel

46. 悪性関節リウマチ


臨床試験数 : 4,325 薬物数 : 2,681 - (DrugBank : 417) / 標的遺伝子数 : 185 - 標的パスウェイ数 : 223
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00000429
(ClinicalTrials.gov)
June 199618/1/2000Calcium Supplements for Bone Health in Juvenile Rheumatoid ArthritisCalcium Supplementation for Bone Mineralization in Juvenile Rheumatoid Arthritis (JRA)Juvenile Rheumatoid ArthritisDrug: Calcium carbonateChildren's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)Completed6 Years18 YearsBoth192Phase 2United States

53. シェーグレン症候群


臨床試験数 : 283 薬物数 : 328 - (DrugBank : 101) / 標的遺伝子数 : 55 - 標的パスウェイ数 : 180
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02370550
(ClinicalTrials.gov)
March 201518/2/2015Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's SyndromeCyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome(CTRIPS): A Prospective, Randomized, Multicenter, Double-Blind Placebo-Controlled TrialSjogren's SyndromeDrug: Cyclosporin A;Drug: Prednisone;Drug: Placebo;Drug: Calcium carbonate DPeking University People's HospitalNULLRecruiting18 Years75 YearsAll240Phase 4China

75. クッシング病


臨床試験数 : 203 薬物数 : 196 - (DrugBank : 51) / 標的遺伝子数 : 62 - 標的パスウェイ数 : 128
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2008-002280-14-FR
(EUCTR)
18/07/200806/06/2008Comparative study of the effect of 4-week treatment with ossein-hydroxyapatite compound versus calcium carbonate on bone biomarkers in young women with low calcium intake. Prospective, monocenter, randomized, open-label, two-period,cross-over trialComparative study of the effect of 4-week treatment with ossein-hydroxyapatite compound versus calcium carbonate on bone biomarkers in young women with low calcium intake. Prospective, monocenter, randomized, open-label, two-period,cross-over trial The Active substance of Osteopor is Ossein Hydroxyapatite.Treatment of processes characterized by decalcification: osteoporosis, Cushing syndrome, thyrotoxicosis.
MedDRA version: 9.1;Level: LLT;Classification code 10006956;Term: Calcium deficiency
Trade Name: OSTEOPOR
Product Name: OSTEOPOR
Product Code: L0006CP03A
INN or Proposed INN: ossein hydroxyapatite
Trade Name: OROCAL
Product Name: OROCAL
INN or Proposed INN: calcium carbonate
Pierre Fabre MédicamentNULLNot RecruitingFemale: yes
Male: no
60Phase 3France

96. クローン病


臨床試験数 : 2,400 薬物数 : 1,417 - (DrugBank : 267) / 標的遺伝子数 : 168 - 標的パスウェイ数 : 214
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01735461
(ClinicalTrials.gov)
December 201222/11/2012Calcium Supplements Strategy for Kidney Stones Prevention in Crohn's PatientsOral Calcium Supplementation, a Strategy to Reduce Kidney Stones in Crohn's Patients Living With a Small Bowel ResectionKidney Calculi;Crohn's DiseaseDietary Supplement: Calcium CarbonateUniversity of British ColumbiaUniversity of Texas Southwestern Medical CenterRecruiting19 YearsN/AAll40N/ACanada

127. 前頭側頭葉変性症


臨床試験数 : 89 薬物数 : 105 - (DrugBank : 33) / 標的遺伝子数 : 40 - 標的パスウェイ数 : 117
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT02862210
(ClinicalTrials.gov)
January 27, 20177/8/2016Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal DementiaLow-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal DementiaFrontotemporal Dementia (FTD)Drug: Lithium Carbonate;Drug: PlaceboColumbia UniversityAlzheimer's Drug Discovery FoundationRecruiting40 Years85 YearsAll60Phase 2United States

235. 副甲状腺機能低下症


臨床試験数 : 88 薬物数 : 129 - (DrugBank : 25) / 標的遺伝子数 : 4 - 標的パスウェイ数 : 6
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03425747
(ClinicalTrials.gov)
October 15, 201927/1/2018Efficacy of Calcium Citrate Versus Calcium Carbonate for the Management of Chronic HypoparathyroidismCALCIUM CITRATE vs CALCIUM CARBONATE FOR THE MANAGEMENT OF CHRONIC HYPOPARATHYROIDISMChronic HypoparathyroidismDrug: Calcium Carbonate;Drug: Calcium CitrateCampus Bio-Medico UniversityNULLCompleted18 Years75 YearsAll26Phase 4Italy
2NCT03249012
(ClinicalTrials.gov)
September 1, 20179/8/2017Quality of Life Related to Different Treatment Protocols for Post-thyroidectomy HypoparathyroidismComparing the Quality of Life Associated With Empiric Calcium Repletion and Parathormone (PTH) Based Calcium Repletion for Post Thyroidectomy HypoparathyroidismHypoparathyroidism Postprocedural;Quality of LifeOther: Empiric use of Calcium Carbonate and Calcitriol;Other: PTH based Calcium Carbonate and Calcitriol repletionCHU de Quebec-Universite LavalNULLRecruiting18 YearsN/AAll120N/ACanada
3NCT04146259
(ClinicalTrials.gov)
January 1, 201729/10/2019Changes in Circulating Sclerostin Levels During Acute Postsurgical HypoparathyroidismChanges in Circulating Sclerostin Levels During Acute Postsurgical HypoparathyroidismHypoparathyroidism PostproceduralDrug: calcium carbonate and alphacalcidolUniversity of AthensNULLCompleted19 YearsN/AFemale109Greece
4NCT01815021
(ClinicalTrials.gov)
April 20137/3/2013A Study Comparing Amorphous Calcium Carbonate (ACC) Versus Crystalline Calcium CCS) in Hypoparathyroidism PatientsA Randomized, Two Phase, Adaptive Then Crossover Open-label, Study Comparing Amorphous Calcium Carbonate (ACC) Supplement Versus Commercially Available Crystalline Calcium Supplements (CCS) in the Management of Primary Hypoparathyroidism.HypoparathyroidismDietary Supplement: amorphous calcium carbonate;Dietary Supplement: crystalline calcium supplementsAmorphical Ltd.NULLCompleted18 Years80 YearsBoth10Phase 1/Phase 2Israel
5JPRN-UMIN000000475
2006/07/0101/09/2006Therapeutic strategy of relative hypoparathyroidism in hemodialysis patients using sevelamer hydrochloride, with special reference to vitamin D administration Relative hypoparathyoidism in maintenance hemodialysis patientsReplacement of calcium carbonate with sevelamer hydrochloride as phosphate binderHokusetsu ROD Study GroupNULLComplete: follow-up complete20years-oldNot applicableMale and Female40Not applicableJapan

299. 嚢胞性線維症


臨床試験数 : 1,696 薬物数 : 1,658 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00004489
(ClinicalTrials.gov)
October 199818/10/1999Randomized Study of Alendronate in Adult Patients With Cystic Fibrosis Related OsteoporosisOsteoporosis;Cystic FibrosisDrug: alendronate sodium;Drug: calcium carbonate;Drug: cholecalciferolUniversity of North CarolinaNULLCompleted18 Years45 YearsBoth60N/AUnited States